• 한국임상약학회지
• /
• 제21권4호
• /
• pp.319-331
• /
• 2011

Purpose: The purpose of this study is to evaluate current criteria for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on the systemic therapy used in the treatment of advanced or metastatic renal cell carcinoma (RCC), by reviewing all available clinical evidences including a variety of clinical practice guidelines. Methods: We searched clinical databases and collected data from published phase 1 through 3 randomized clinical trials on all systemic therapies used in RCC, including novel targeted therapies. Additionally, current clinical practice guidelines on the management of kidney cancer or RCC were reviewed. Based on the collected data we evaluated the appropriateness of the HIRA criteria for insurance coverage on the systemic therapy of RCC whether they are evidence-based and up to date. Results: On the basis of the collected data we concluded that there was a need for a revision in HIRA criteria for systemic therapy of RCC. Despite recent emerging therapeutic advances and changes in therapeutic strategies of management of RCC, some of anticancer regimens were inappropriately listed even though they were not proven to provide efficacy or safety superior to those of other therapies. We thus proposed an updated recommendation based on current clinical evidences. Conclusion: Systemic therapy of RCC is being rapidly changed with the advancement of understanding of the molecular biology of cancer. Consequently newly developed targeted therapies are becoming the standard therapy in the management of medically or surgically unresectable advanced or metastatic RCC. To provide effective and safe therapy to patients with RCC, the criteria for insurance coverage should be made carefully taking into consideration of most up-to-date and high-quality clinical evidences, and should be continuously reviewed so as to reflect evidence-based clinical practice.

• Radiation Oncology Journal
• /
• 제34권2호
• /
• pp.128-134
• /
• 2016

Purpose: To evaluate the clinical outcomes of patients who underwent radiation therapy with or without targeted molecular therapy for the treatment of spinal metastasis from renal cell carcinoma (RCC). Materials and Methods: A total of 28 spinal metastatic lesions from RCC patients treated with radiotherapy between June 2009 and June 2015 were retrospectively reviewed. Thirteen lesions were treated concurrently with targeted molecular therapy (concurrent group) and 15 lesions were not (nonconcurrent group). Local control was defined as lack of radiographically evident local progression and neurological deterioration. Results: At a median follow-up of 11 months (range, 2 to 58 months), the 1-year local progression-free rate (LPFR) was 67.0%. The patients with concurrent targeted molecular therapy showed significantly higher LPFR than those without (p = 0.019). After multivariate analysis, use of concurrent targeted molecular therapy showed a tendency towards improved LPFR (hazard ratio, 0.13; 95% confidence interval, 0.01 to 1.16). There was no difference in the incidence of systemic progression between concurrent and nonconcurrent groups. No grade ${\geq}2$ toxicities were observed during or after radiotherapy. Conclusion: Our study suggests the possibility that concurrent use of targeted molecular therapy during radiotherapy may improve LPFR. Further study with a large population is required to confirm these results.

• 한국임상약학회지
• /
• 제34권3호
• /
• pp.184-193
• /
• 2024

Background: Sunitinib, commonly used for metastatic renal cell carcinoma (mRCC), often induces hypothyroidism, affecting 27 to 85% of patients. There are clues suggesting an association between sunitinib-induced hypothyroidism and improved survival outcomes. This study aims to identify the predictive factors of sunitinib-induced hypothyroidism and evaluate whether the occurrence of overt or subclinical hypothyroidism predicts tumor outcome in patients with mRCC. Methods: Patients administered to sunitinib for mRCC was included in this retrospective study. Log-rank test and Cox proportional hazards model were conducted to identify predictive factors of hypothyroidism and prognostic factors of progression-free survival (PFS) and overall survival (OS). Results: A total of 156 patients with mRCC treated with sunitinib were included. Predictive factors of sunitinib-induced hypothyroidism were female (odds ratio (OR), 2.77), sunitinib-induced hypertension (OR, 2.99) and dose reduction of sunitinib due to intolerance (OR, 3.57). Sunitinib-induced overt hypothyroidism was a significant prognostic factor in predicting PFS and OS (hazard ratio, 0.38 and 0.23, respectively). Thyroid hormone replacement did not have an influence on PFS and OS. Conclusions: Female patients, patients who experienced sunitinib-induced hypertension and sunitinib dose reduction are at higher risk of hypothyroidism and need close monitoring. Overt hypothyroidism is a strong prognostic factor of sunitinib treatment outcome in mRCC patients and thyroid hormone replacement does not have a negative effect on tumor outcome.

• 한국임상수의학회지
• /
• 제30권4호
• /
• pp.292-295
• /
• 2013

9세령의 수컷 도베르만견이 5개월간 간헐적인 혈뇨, 구토 및 당뇨증상을 보여 동물병원에 내원하였다. 초음파상에서 종대된 좌측 신장의 수질부위에 종괴가 발견되었다. 육안적으로 좌측 신장의 피질 및 수질부는 현저하게 위축되어 있었으며 신우 부위는 종괴로 인하여 확장된 수신증을 나타내었다. 크기 4~5.5 cm의 유두상으로 돌출된 꽃자루와 같은 단일종괴가 신우 부위에 있으며, 요관으로 뻗어 있었다. 병리조직학적으로 종괴는 나뭇가지 모양으로 무수히 돌출된 유두상의 돌기들로 구성되어 있었다. 이 돌기들은 섬유혈관성 중심부와 뚜렷한 이형태성을 가지는 여러 층의 종양화된 이행상피들로 피복되어 있었다. 면역조직화학염색을 실시한 결과 종양세포들은 사이토케라틴(cytokeratin: CK) 7, 19, CK clone MNF116 및 CK HMW에 대해서 양성을 보였으나 CK 8 LMW에서는 음성 반응을 나타내었다. 육안적인 특징, 병리조직학적 소견 및 면역조직화학염색에 의한 사이토케라틴의 반응성을 토대로 이 종괴는 개의 신우에서 발생한 이행상피암종으로 진단되었다.

• Journal of Chest Surgery
• /
• 제31권11호
• /
• pp.1097-1101
• /
• 1998

신세포암은 환자의 약 5∼10%에서 하대정맥을 침범한다. 이러한 경우 수술적으로 함께 제거하는 것이 가장 좋은 치료로 되어있다. 최근에는 간정맥 유입로 상부에 위치한 하대정맥내의 종양 혈전 제거술의 경우 체외 순환을 통한 순환 정지 방법이 사용되고 있다. 본 교실에서는 근치적 신적출술과 함께 하대정맥내의 종양 혈전 제거술을 4례 치험하였다. 모든 환자에서 간정맥이하의 하대정맥 혈전으로 체외 순환의 도움 없이 일반적인 방법으로 시행되었으나, 그 중 한 환자에서 간정맥의 유입로보다 상부에 위치한 하대정맥혈전이 재발되어 순환정지후 혈전제거술을 시행하였다. 네 명의 환자 모두 특별한 문제없이 회복되었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권14호
• /
• pp.5687-5690
• /
• 2015

Background: Factors predictive of survival have been identified in Western patients with metastatic clear cell renal cell carcinoma (mCCRCC) treated with sunitinib. Less is known, however, about factors predictive of survival in Japanese patients. This study evaluated factors prognostic of survival in Japanese patients with mCCRCC treated with first-line sunitinib. Materials and Methods: This retrospective study evaluated 46 consecutive Japanese mCCRCC patients treated with sunitinib as first line therapy. Clinical and biochemical markers associated with progression-free survival (PFS) were analyzed, with prognostic factors selected by uniand multivariate Cox regression analyses. Results: Univariate analysis showed that factors significantly associated with poor PFS included Memorial Sloan-Kettering Cancer Center poor risk scores, International Metastatic RCC Database Consortium poor risk and high (>0.5 mg/dl) serum C-reactive protein (CRP) concentrations (p<0.001 each). Multivariate analysis showed that high serum CRP was independently associated with poorer PFS (p=0.040). Six month disease control rate (complete response, partial response and stable disease) in response to sunitinib was significantly higher in patients with normal (${\leq}0.5mg/dl$) than elevated baseline CRP (p<0.001). Conclusions: CRP is a significant independent predictor of PFS for Japanese patients with mCCRCC treated with first-line sunitinib. Pretreatment CRP concentration may be a useful biomarker predicting response to sunitinib treatment.

• Biomolecules & Therapeutics
• /
• 제5권2호
• /
• pp.125-132
• /
• 1997

Cisplatin, a platinum-complex, is currently one of the most effective compounds used in the treat-ment of solid tumors. However, its use is limited by severe side effects such as renal toxicity. Our platinum-based drug discovery program is aimed at developing drugs capable of diminishing toxicity and improving selective cytotoxicity. We synthesized new Pt (II) complex analogue containing 1,2-diaminocyclohexane (DACH) as carrier ligand and 1,2-bis (diphenylphosphino) ethane (DPPE) as a leaving group. Furthermore, nitrate was added to improve the solubility. A new series of [Pt(cia-DACH)(DPPE)] . $2NO_3$ (PC) was synthes-ized and characterized by their elemental analysis and by various spectroscopic techniques [infrared (IR), $_{13}$carbon nuclear magnetic resonance (NMR)] .PC demonstrated acceptable and significant antitumor activity against SKOV-3 and OVCAR-3 human ovarian carcinoma cell lines as compared with that of cisplatin. The cytotoxicity of PC in normal cells was found quite less than that of cisplatin using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), ($^3$H)thymidine uptake and glucose consumption tests in rabbit renal proximal tubular cells, human renal cortical cells and tissues. In conclusion, PC is considered to be more selective cytotoxicity toward human ovarian cancer cells than normal human/rabbit kidney cells.

• The Korean Journal of Physiology and Pharmacology
• /
• 제7권2호
• /
• pp.111-117
• /
• 2003

Cisplatin is often effective in cancer treatment, but its clinical use is limited because of its nephrotoxicity. We have synthesized new platinum(II) coordination complexes (PC-1 & PC-2) containing trans-${\iota}$ and cis-1,2-diaminocyclohexane (DACH) as carrier ligands and L-3 -phenyllactic acid (PLA) as a leaving group with the aim of reducing nephrotoxicity but maintaining its anticancer activity. In this study, new platinum(II) complex compounds were evaluated for selective cytotoxicity on cancer cell-lines and normal kidney cells. The new platinum complexes have demonstrated high efficacy in the cytotoxicity against human bladder carcinoma cell-lines (T-24/HT-1376). The cytotoxicity of these compounds against rabbit proximal renal tubular cells and human renal cortical tissues, was determined by MTT assay, the [3H]-thymidine uptake and glucose consumption test, and found to be quite less than those of cisplatin. Based on our results, these novel platinum compounds appear to be valuable lead compounds with high efficacy and low nephrotoxicity.

• International Journal of Oral Biology
• /
• 제42권2호
• /
• pp.79-83
• /
• 2017

Abnormal HLA-G expression occurs in various diseases such as melanoma, renal cell carcinoma, asthma, and classic Hodgkin's lymphoma. The purpose of this study was to determine whether HLA-G gene is linked with oral squamous cell carcinoma (OSCC). To investigate the possible link with susceptibility to OSCC, 54 OSCC patients and 120 healthy controls were enrolled in this study. HLA-G 14bp insertion/deletion polymorphism is in 3'-untranslated region of HLA-G gene. HLA-G 14bp insertion/deletion polymorphism was analyzed using the polymerase chain reaction (PCR) method. For the analysis of genetic data, SPSS18.0 program was used. Logistic regression models were performed for odds ratio (OR), 95 percent confidence interval (CI), and P value. There was a significant difference in distribution allele between OSCC patients and control subjects (OR=0.018, 95% CI=0.002-0.131, p<0.001). Our results suggest that HLA-G 14bp insertion/deletion polymorphism may be linked with susceptibility to OSCC in the Korean population.

• 대한영상의학회지
• /
• 제82권4호
• /
• pp.994-999
• /
• 2021

수술 이후 10년 이상이 경과된 후 발생하는 후발성 전이와 더불어 기관지 내 전이는 신세포암의 특징적인 소견이다. 본 증례 보고는 신절제술 20년 후에 세분절 기관지에서 발생한 신세포암의 단일성 기관지 내 전이의 사례를 보고하고 문헌을 고찰하고자 한다. 71세의 남자가 폐렴을 주소로 병원에 입원하였다. 흉부 단순촬영에서 우하폐야의 다발성 결절성 병변을 보여 흉부 컴퓨터단층사진을 촬영하였고 우폐의 염증성 침윤과 함께 우하엽에 4.3 cm 크기의 경계가 좋은 길쭉한 고형성 종괴를 발견하였다. 포함된 상복부에 우측 신절제술의 흔적으로 20년 전에 투명 신세포암으로 우측 신장 절제술을 받았던 기왕력을 확인하였다. 병변은 폐우하엽 절제술로 제거하였고, 병리학적으로 기관지 내 전이성 투명신세포암으로 진단되었다. 신세포암의 병력이 있다면 절제술 후 수십 년이 지난 후라도 기관지 내 종양에 대하여 신세포암의 기관지 내 전이 가능성을 고려하여야 한다.